FIELD: biotechnologies.
SUBSTANCE: application of medicinal agent is explained, which contains bucindolol, to produce medicine to treat patient suffering cardiovascular disease. In which specified patient lacks detected levels of protein β1AR with glycine in position 389. Specified patient is homozygous by cysteine in position 1165 in coding nucleotide sequence of both allels β1AR. Specified patient lacks detected levels of protein α2ACAR with deletion in positions 322-325. Or specified patient is homozygous in position 964-975 in coding nucleotide sequence of both allels α2ACAR of wild type. Medicinal agent is described, which contains bucindolol, to treat patient suffering cardiovascular disease, where specified patients demonstrates above-described criteria. Method for treatment of impaired cardiac function is presented with application of bucindolol based on genotype of patient with polymorphism in genes of adrenergic receptors including gene β1-adrenergic receptor (β1AR) and α2c-adrenergic receptor (α2cAR).
EFFECT: invention may be used to treat impaired cardiac function in patients suffering diabetes.
15 cl, 29 dwg, 9 tbl, 11 ex
